Novavax Initiates Phase 3 Efficacy Trial of COVID-19 Vaccine in the United Kingdom | Novavax Inc. – IR Site

Clinical trial to enroll up to 10,000 volunteers across the UK to assess whether NVX-CoV2373 is effective in the prevention of COVID-19 GAITHERSBURG, Md., Sept. 24, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has initiated…

Read the full article here

Related Articles